Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 16/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5087414 | 0.93 | ADORA1 (0.58) | ADORA1ADORA3ADORA2AADORA2BTDP1 | |
| SCHEMBL14288901 | 0.92 | ADORA1 (0.42) | ADORA1ADORA3KDM4EGAAMARS1 | |
| SCHEMBL5087457 | 0.91 | ADORA1 (0.52) | ADORA1ADORA3KDM4EGAAADORA2A | |
| SCHEMBL5089499 | 0.89 | ADORA1 (0.51) | ADORA1ADORA3KDM4EGAAADORA2A | |
| SCHEMBL5087425 | 0.87 | ADORA1 (0.61) | ADORA1ADORA3KDM4EADORA2AADORA2B | |
| SCHEMBL5090462 | 0.85 | ADORA1 (0.50) | ADORA1ADORA3KDM4EGAAADORA2A | |
| SCHEMBL5087423 | 0.85 | ADORA1 (0.68) | ADORA1ADORA3KDM4EADORA2AADORA2B | |
| SCHEMBL5090413 | 0.83 | ADORA1 (0.53) | ADORA1ADORA3KDM4EGAAADORA2A | |
| SCHEMBL5089422 | 0.83 | ADORA1 (0.61) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL14288900 | 0.83 | ADORA1 (0.44) | ADORA1ADORA3KDM4EGAAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009531-A1 | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | GPR119, IAPP, GLP1R | ADORA1 680/4885ADORA3 187/4885KDM4E 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.